We are live on ! Find out more
NUVA

NuVasive, Inc.

Delisted

NUVA was delisted on the 31st of August, 2023.

257 hedge funds and large institutions have $3.14B invested in NuVasive, Inc. in 2016 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 97 increasing their positions, 81 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more call options, than puts

Call options by funds: $5.4M | Put options by funds: $2.96M

31% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 36

27% more capital invested

Capital invested by funds: $2.48B → $3.14B (+$668M)

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

20% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 81

3% more funds holding

Funds holding: 249257 (+8)

Holders
257
Holders Change
+8
Holders Change %
+3.21%
% of All Funds
6.86%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.13%
New
47
Increased
97
Reduced
81
Closed
36
Calls
$5.4M
Puts
$2.96M
Net Calls
+$2.44M
Net Calls Change
+$1.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Thrivent Financial for Lutherans
26
Thrivent Financial for Lutherans
Minnesota
$36.5M -$3.79M -70,119 -10%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$35.6M -$2.6M -48,141 -7%
Wells Fargo
28
Wells Fargo
California
$32M +$12.2M +225,561 +73%
BA
29
BlackRock Advisors
Delaware
$30.4M -$2.86M -52,937 -9%
RCAMU
30
Rothschild & Co Asset Management US
Connecticut
$25.4M -$394K -7,288 -2%
HRCM
31
Hood River Capital Management
Florida
$25.3M +$22.9M +423,759 New
O
32
OppenheimerFunds
New York
$24.8M +$5.9M +109,197 +36%
Neuberger Berman Group
33
Neuberger Berman Group
New York
$23.8M -$3.08M -57,068 -13%
Ameriprise
34
Ameriprise
Minnesota
$22.4M +$7.62M +140,894 +60%
CWM
35
CIBC World Markets
New York
$22.2M +$13.1M +243,202 +189%
TA
36
Teachers Advisors
New York
$21.6M +$577K +10,681 +3%
HighTower Advisors
37
HighTower Advisors
Illinois
$21.6M -$423K -7,819 -2%
Two Sigma Investments
38
Two Sigma Investments
New York
$21.6M +$17.9M +331,173 +1,106%
Principal Financial Group
39
Principal Financial Group
Iowa
$21.6M +$731K +13,521 +4%
Jennison Associates
40
Jennison Associates
New York
$21.1M -$323K -5,983 -2%
Geode Capital Management
41
Geode Capital Management
Massachusetts
$20.3M -$1.15M -21,307 -6%
Renaissance Technologies
42
Renaissance Technologies
New York
$19.1M +$3.19M +58,988 +23%
PCM
43
Penn Capital Management
Pennsylvania
$18.7M -$5.66M -104,732 -25%
SAM
44
Sentinel Asset Management
Vermont
$17M +$790K +14,607 +5%
RIM
45
Rainier Investment Management
Washington
$16.2M +$14.7M +271,030 New
Two Sigma Advisers
46
Two Sigma Advisers
New York
$15.9M +$5.37M +99,300 +59%
ACPU
47
Arrowgrass Capital Partners (US)
Delaware
$15.7M +$8.33M +154,120 +141%
UBS Group
48
UBS Group
Switzerland
$15.7M +$13.1M +242,646 +1,231%
Deutsche Bank
49
Deutsche Bank
Germany
$15.7M +$11M +203,416 +346%
O
50
OrbiMed
New York
$14.8M -$67M -1,239,900 -83%

NUVA Hedge Fund Activity: Q2 2016 in Review

257 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NuVasive, Inc. (NUVA) for Q2 2016, worth a combined $3.14B — up 27% from $2.48B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new NUVA positions and 36 closed out — a net gain of 11 holders — while 97 added to existing stakes and 81 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $63.5M. The largest seller was OrbiMed, cutting an estimated $67M.

  • 257 institutional investors held NuVasive, Inc. (NUVA) as of Q2 2016, up from 249 in Q1 2016.
  • Funds reported $3.14B of NuVasive, Inc. stock for Q2 2016, up 27% quarter-over-quarter.
  • 47 funds opened new NuVasive, Inc. positions in Q2 2016 and 36 closed out, a net change of +11 holders.
  • The largest NuVasive, Inc. buyer in Q2 2016 was Goldman Sachs, an estimated $63.5M added.
  • The largest NuVasive, Inc. seller in Q2 2016 was OrbiMed, an estimated $67M sold.

Based on aggregated 13F filings for Q2 2016.